Gastroesophageal Reflux Disease — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for gastroesophageal reflux disease. 47 active patents protecting 6 drugs from 5+ originators. First major cliff: 2026. Daily refresh.

6
Approved drugs
47
Active US patents
62/100
Avg vulnerability
$1.3B
Annual revenue covered

Originators in Gastroesophageal Reflux Disease

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Takeda 22 patents AstraZeneca (originally Astra AB) 10 patents Hikma 7 patents Generic (originally Yamanouchi/Merck) 7 patents Pfizer 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating gastroesophageal reflux disease. Each bar = one year. Y-axis scaled to peak year (13 patents).

13
26
4
27
4
28
6
29
5
30
2
32
4
36
1
38
7
39
1
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Dexilant
DEXLANSOPRAZOLE
 Takeda 22 63 $300M 2026-07-17
Prilosec
omeprazole
 AstraZeneca (originally Astra AB) 10 37 $1.0B 2036-12-08
Reglan
Metoclopramide Hydrochloride
 Hikma 7 75 — 2029-12-22
Pepcid
famotidine
 Generic (originally Yamanouchi/Merck) 5 73 — 2026-07-18
Prevacid
lansoprazole
 Generic (originally Takeda) 2 49 — 2036-04-21
Pantoprazole Sodium
Pantoprazole Sodium
 Pfizer 1 73 — 2026-12-07

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8501228 Pepcid method of use 85 2026-07-18
8067451 Pepcid method of use 85 2026-07-18
12194008 Reglan method of use 81 2029-12-22
12194009 Reglan method of use 81 2029-12-22
8461187 Dexilant other 80 2026-07-17
8461187 Dexilant other 80 2026-07-17
8461187 Dexilant other 80 2026-07-17
7544370 Pantoprazole Sodium other 80 2026-12-07
7790755 Dexilant other 80 2027-02-02
7790755 Dexilant other 80 2027-02-02

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10835488 Prilosec formulation 25 2036-12-08
10076494 Prilosec formulation 25 2036-12-08
11633478 Prilosec formulation 33 2039-07-16
11103492 Prilosec formulation 33 2039-07-16
10751333 Prilosec formulation 33 2039-07-16
12042539 Prilosec formulation 38 2039-07-16
12329752 Prilosec formulation 38 2039-07-16
12440566 Prilosec formulation 38 2039-07-16
11077055 Prevacid formulation 42 2036-04-21
11771686 Prilosec method of use 53 2040-03-01

Related